Harmony Biosciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.10.24	Harmony Biosciences Holdings, Inc Q3 Profit Increases, Beats Estimates (RTTNews)
25.06.24	Harmony Biosciences Says FDA Rejected Petition Against Wakix For Narcolepsy Treatment (RTTNews)
30.05.24	Biotech Stocks Facing FDA Decision In June 2024 (RTTNews)
21.02.24	Harmony Biosciences Receives FDA Priority Review For Wakix (RTTNews)
20.02.24	Harmony Biosciences Receives FDA's Orphan Drug Designation For Pitolisant In Prader-Willi Syndrome (RTTNews)
07.12.23	HARMONY BIOSCIENCES ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT IN ADULT PATIENTS WITH MYOTONIC DYSTROPHY TYPE 1 (PR Newswire)
05.12.23	HARMONY BIOSCIENCES TO PRESENT RESULTS FROM BEHAVIORAL STUDY IN 22Q11.2 DELETION SYNDROME AT AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING (PR Newswire)
16.11.23	HARMONY BIOSCIENCES TO PARTICIPATE IN PIPER SANDLER 35th ANNUAL HEALTHCARE CONFERENCE (PR Newswire)
15.11.23	HARMONY BIOSCIENCES RANKED AMONG TOP 25 FASTEST-GROWING COMPANIES IN NORTH AMERICA ON THE 2023 DELOITTE TECHNOLOGY FAST 500™ (PR Newswire)
08.11.23	HARMONY BIOSCIENCES APPOINTS PETER ANASTASIOU TO ITS BOARD OF DIRECTORS (PR Newswire)
26.10.23	HARMONY BIOSCIENCES SHOWCASES THE NEWEST PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD RECIPIENTS (PR Newswire)
17.10.23	HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS ON OCTOBER 31, 2023 (PR Newswire)
13.10.23	HARMONY BIOSCIENCES ANNOUNCES TOPLINE DATA FROM PHASE 3 INTUNE STUDY EVALUATING PITOLISANT IN PATIENTS WITH IDIOPATHIC HYPERSOMNIA (PR Newswire)
11.10.23	HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE (PR Newswire)
05.10.23	HARMONY BIOSCIENCES PRESENTS NEW SECONDARY OUTCOME DATA FROM PHASE 2 SIGNAL DETECTION STUDY IN PATIENTS WITH PRADER-WILLI SYNDROME (PR Newswire)
27.09.23	HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. (PR Newswire)
20.09.23	HARMONY BIOSCIENCES PRESIDENT & CEO JEFFREY M. DAYNO, M.D., NAMED TO 2023 PHARMAVOICE 100 LIST OF TOP INDUSTRY LEADERS (PR Newswire)
13.09.23	HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE (PR Newswire)
07.09.23	HARMONY BIOSCIENCES ANNOUNCES US FOOD & DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT FOR TREATMENT OF IDIOPATHIC HYPERSOMNIA (PR Newswire)
28.08.23	HARMONY BIOSCIENCES REITERATES CONFIDENCE IN WAKIX® (PITOLISANT) PATENTS FOLLOWING FAVORABLE DECISION BY U.S. PATENT AND TRADEMARK OFFICE (USPTO) TO DENY PETITION FOR REEXAMINATION   (PR Newswire)
28.08.23	Will Harmony's INTUNE Trial Data Strike A Chord? (RTTNews)
14.08.23	Harmony Biosciences To Acquire Zynerba Pharma For Up To $200 Mln (RTTNews)
14.08.23	HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. (PR Newswire)
01.08.23	HARMONY BIOSCIENCES ANNOUNCES $125 MILLION SHARE REPURCHASE PROGRAM (PR Newswire)
27.07.23	HARMONY BIOSCIENCES ENTERS INTO $185 MILLION TERM LOAN FACILITY (PR Newswire)
25.07.23	Harmony Biosciences Announces Funding for Unique Community Initiatives Through its Patients and Progress at the Heart Awards Programs (PR Newswire)
20.07.23	HARMONY BIOSCIENCES ANNOUNCES PLANS TO INITIATE PHASE 3 REGISTRATIONAL STUDY OF PITOLISANT IN PRADER-WILLI SYNDROME FOLLOWING POSITIVE END-OF-PHASE 2 MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION (PR Newswire)
18.07.23	HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS ON AUGUST 1, 2023 (PR Newswire)
06.06.23	HARMONY BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME AT SLEEP 2023 (PR Newswire)
30.05.23	HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 44th ANNUAL GLOBAL HEALTHCARE CONFERENCE (PR Newswire)
25.05.23	HARMONY BIOSCIENCES COMPLETES ENROLLMENT OF PHASE 3 REGISTRATIONAL INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA (PR Newswire)
10.05.23	HARMONY BIOSCIENCES TO PRESENT NEW WAKIX® (PITOLISANT) SAFETY AND EFFICACY DATA AT SLEEP 2023 ANNUAL MEETING (PR Newswire)
24.04.23	HARMONY BIOSCIENCES ANNOUNCES JEFFREY M. DAYNO, M.D. APPOINTED PRESIDENT & CHIEF EXECUTIVE OFFICER (PR Newswire)
20.04.23	HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS ON MAY 2, 2023 (PR Newswire)
29.03.23	HARMONY BIOSCIENCES ANNOUNCES ACCELERATED TIMELINE FOR PHASE 3 INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA (PR Newswire)
06.03.23	HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES (PR Newswire)
28.02.23	HARMONY BIOSCIENCES CONTINUES COMMUNITY COMMITMENT IN 2023 WITH PATIENTS AT THE HEART AND PROGRESS AT THE HEART NONPROFIT FUNDING PROGRAMS (PR Newswire)
17.02.23	HARMONY BIOSCIENCES CERTIFIED AS A GREAT PLACE TO WORK® FOR FIFTH CONSECUTIVE YEAR (PR Newswire)
07.02.23	HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS ON FEBRUARY 21, 2023 (PR Newswire)
06.01.23	HARMONY BIOSCIENCES APPOINTS JEFFREY M. DAYNO, MD AS INTERIM CEO AND EXPANDS ROLE OF JEFF ARONIN TO EXECUTIVE CHAIRMAN (PR Newswire)
22.12.22	HARMONY BIOSCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE (PR Newswire)
09.11.22	HARMONY BIOSCIENCES TO PARTICIPATE IN PIPER SANDLER 34th ANNUAL HEALTHCARE CONFERENCE (PR Newswire)
01.11.22	HARMONY BIOSCIENCES ANNOUNCES TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH PRADER-WILLI SYNDROME (PR Newswire)
18.10.22	HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS ON NOVEMBER 1, 2022 (PR Newswire)
10.10.22	Pre-market Movers: HRMY, MPTI, LUCY, NURO, ACMR… (RTTNews)
22.09.22	HARMONY BIOSCIENCES ANNOUNCES 2022 FUNDING RECIPIENTS OF PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD PROGRAMS (PR Newswire)
17.08.22	HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES (PR Newswire)
03.08.22	ATRC Sees 18-21% Revenue Growth, EVH Q2 Results Beat Estimates, EXAS Trims Outlook, HRMY On Watch... (RTTNews)
19.07.22	HARMONY BIOSCIENCES ANNOUNCES DATE OF SECOND QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
06.06.22	HARMONY BIOSCIENCES PRESENTS POST-HOC ANALYSIS OF WAKIX® (PITOLISANT) PIVOTAL DATA IN ADULTS WITH HIGH BURDEN OF NARCOLEPSY SYMPTOMS (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	77.78	3.85 %	K V
CieFinRichemont	139.05	3.58 %	K V
UBS Group	29.21	2.64 %	K V
Sika	217.70	2.25 %	K V
Lonza Grp	541.80	1.46 %	K V
Swiss Re	132.60	-0.08 %	K V
Swisscom	504.00	-0.10 %	K V
Sonova Hldg	294.30	-0.71 %	K V
Nestle	74.02	-0.91 %	K V
Givaudan	3’888.00	-1.44 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Harmony Biosciences

Aktien Top/Flop

Meistgelesene Nachrichten